CN117247944A - 抗前-s1 hbv抗体 - Google Patents

抗前-s1 hbv抗体 Download PDF

Info

Publication number
CN117247944A
CN117247944A CN202310981391.9A CN202310981391A CN117247944A CN 117247944 A CN117247944 A CN 117247944A CN 202310981391 A CN202310981391 A CN 202310981391A CN 117247944 A CN117247944 A CN 117247944A
Authority
CN
China
Prior art keywords
nucleotide sequence
seq
variable region
chain variable
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310981391.9A
Other languages
English (en)
Chinese (zh)
Inventor
隋建华
李丹
李文辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Biological Sciences Beijin
Original Assignee
National Institute of Biological Sciences Beijin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute of Biological Sciences Beijin filed Critical National Institute of Biological Sciences Beijin
Publication of CN117247944A publication Critical patent/CN117247944A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202310981391.9A 2015-05-22 2016-05-23 抗前-s1 hbv抗体 Pending CN117247944A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/079534 2015-05-22
CN2015079534 2015-05-22
CN201680029377.7A CN107614525B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体
PCT/CN2016/082985 WO2016188386A1 (en) 2015-05-22 2016-05-23 Anti-Pre-S1 HBV Antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680029377.7A Division CN107614525B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体

Publications (1)

Publication Number Publication Date
CN117247944A true CN117247944A (zh) 2023-12-19

Family

ID=57392535

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202310981391.9A Pending CN117247944A (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体
CN201680029377.7A Active CN107614525B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体
CN202110657776.0A Active CN113527470B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201680029377.7A Active CN107614525B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体
CN202110657776.0A Active CN113527470B (zh) 2015-05-22 2016-05-23 抗前-s1 hbv抗体

Country Status (10)

Country Link
US (3) US20180094047A1 (enExample)
EP (2) EP3978521A1 (enExample)
JP (2) JP6820278B2 (enExample)
KR (1) KR102770671B1 (enExample)
CN (3) CN117247944A (enExample)
ES (1) ES2896275T3 (enExample)
HK (1) HK1243429A1 (enExample)
MA (1) MA42137A (enExample)
RU (1) RU2739955C2 (enExample)
WO (1) WO2016188386A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180094047A1 (en) 2015-05-22 2018-04-05 Huahui Health Ltd. Anti-pre-s1 hbv antibodies
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
WO2020130138A1 (ja) * 2018-12-21 2020-06-25 国立大学法人広島大学 抗ｐｒｅＳ１抗体およびその用途
US12509504B2 (en) 2019-07-20 2025-12-30 Huahui Health Ltd. Method of treating HBV infection by using anti-pre-S1 HBV antibodies
KR102680147B1 (ko) * 2021-06-15 2024-07-03 에이피트바이오 주식회사 B형 간염바이러스 preS1항원의 간세포 수용체 결합부위에 특이적으로 결합하는 인간 항체 및 이의 용도
WO2023039243A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
CN116568808A (zh) * 2021-10-19 2023-08-08 北京三诺佳邑生物技术有限责任公司 特异性结合乙型肝炎病毒表面抗原pre-S1的抗体及其应用
CN114685663B (zh) * 2022-04-07 2023-09-08 西南大学 一种抗胆固醇依赖性细胞溶素的抗体及其应用
CN117304308A (zh) * 2022-06-20 2023-12-29 华辉安健（北京）生物科技有限公司 抗乙型肝炎病毒的抗体及其制备和应用
CN121159708A (zh) * 2025-09-26 2025-12-19 深圳新诺微环生物科技有限公司 特异性结合乙肝表面抗原的双特异性抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
CA2041772A1 (en) * 1990-05-11 1991-11-12 Larry T. Mimms Monoclonal antibodies to pres2 and pres1 polypeptide of the hepatitis b viral envelope
RU2146706C1 (ru) * 1992-11-06 2000-03-20 Новартис Аг Моноклональное антитело, связывающееся с поверхностным антигеном вируса гепатита b, fab-фрагмент и способ снижения уровня циркулирующего поверхностного антигена вируса гепатита b у пациента
KR100345463B1 (ko) 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
CN1216914C (zh) * 2000-05-17 2005-08-31 韩国科学技术研究院 对hbv表面抗原pre－s1具有特异性的人源化抗体
KR100423614B1 (ko) * 2001-05-16 2004-03-22 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
EP1281761A1 (en) 2001-07-27 2003-02-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Hepatitis B virus pre-S1 derived synthetic polypeptides and their use thereof.
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CN1733798B (zh) * 2005-08-12 2012-07-04 上海贺普生物科技有限公司 乙型肝炎病毒表面l蛋白相关肽
WO2011045079A1 (en) * 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
CN104662036B (zh) * 2012-04-25 2018-11-09 华辉安健（北京）生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用
US20180094047A1 (en) 2015-05-22 2018-04-05 Huahui Health Ltd. Anti-pre-s1 hbv antibodies

Also Published As

Publication number Publication date
CN107614525B (zh) 2021-07-06
JP2018519804A (ja) 2018-07-26
US20220275060A9 (en) 2022-09-01
US20200109186A1 (en) 2020-04-09
EP3978521A1 (en) 2022-04-06
US20180148496A1 (en) 2018-05-31
US20180094047A1 (en) 2018-04-05
JP7304320B2 (ja) 2023-07-06
EP3298038A1 (en) 2018-03-28
ES2896275T3 (es) 2022-02-24
KR102770671B1 (ko) 2025-02-24
CN107614525A (zh) 2018-01-19
KR20180009780A (ko) 2018-01-29
RU2739955C2 (ru) 2020-12-30
US10544205B2 (en) 2020-01-28
CN113527470B (zh) 2023-08-25
MA42137A (fr) 2021-04-07
JP2020171311A (ja) 2020-10-22
CN113527470A (zh) 2021-10-22
RU2017145085A3 (enExample) 2020-01-23
RU2017145085A (ru) 2019-06-24
WO2016188386A1 (en) 2016-12-01
HK1243429A1 (zh) 2018-07-13
EP3298038A4 (en) 2019-04-24
EP3298038B1 (en) 2021-08-04
JP6820278B2 (ja) 2021-01-27
US11485774B2 (en) 2022-11-01

Similar Documents

Publication Publication Date Title
US11485774B2 (en) Anti-pre-S1 HBV antibodies
US12054538B2 (en) Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
Li et al. A potent human neutralizing antibody Fc-dependently reduces established HBV infections
JP7098629B2 (ja) 抗ｐｄ－１モノクローナル抗体、その製造方法及び用途
CN101512008A (zh) 白介素-13结合蛋白
WO2013090644A2 (en) Anti-hiv antibodies having increased potency and breadth
JP2019081766A (ja) インターフェロンアルファ及びオメガ抗体アンタゴニスト
US20210332149A1 (en) Anti-human tlr7 antibody
WO2022058618A2 (en) Sars-cov2 antibodies
TW202204396A (zh) 抗hbv抗體及使用方法
WO2022141378A1 (zh) 一种抗pd-1的单域抗体
WO2022210830A1 (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体
HK40095854A (zh) 抗前-s1 hbv抗体
CN115975020A (zh) 靶向sars-cov-2s蛋白的抗原结合蛋白及其应用
WO2014006230A1 (en) Il-20 epitopes and il-20 ligands
KR20020027208A (ko) Ｂ형 간염 바이러스의 표면항원 ｓ에 대한 인간화 항체 및그의 제조방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40095854

Country of ref document: HK